Anne Freimoser–Grundschober

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

Christian Klein, Inja Waldhauer, Valeria Nicolini et al. · OncoImmunology · 2017 · 283 citations · Full text

Life Sciences, Immunology, Oncology +17

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells

Laura Codarri Deak, Valeria Nicolini, Masao Hashimoto et al. · Nature · 2022 · 268 citations · Full text

Life Sciences, Cancer Biology, Immunology +16

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

Christina Claus, Claudia Ferrara, Wei Xu et al. · Science Translational Medicine · 2019 · 266 citations · Full text

Medicine, Immunology, Oncology +17

CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies

Marina Bacac, Sara Colombetti, Sylvia Herter et al. · Clinical Cancer Research · 2018 · 238 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease

Laurence B. Peterson, Sarah Howlett, Marcin Ł. Pękalski et al. · Journal of Autoimmunity · 2018 · 150 citations · Full text

Life Sciences, Immunology, Molecular Medicine +16